scholarly journals Synergistic activity from Hymenaea courbaril L. and Stryphnodendron adstringens (Mart.) Coville against multidrug-resistant bacteria strains

2015 ◽  
Vol 9 (26) ◽  
pp. 741-748 ◽  
Author(s):  
Neves Camargos Vidyleison ◽  
Marjorie Silva Herrera Karina ◽  
dos Santos Michelli ◽  
Souza Carvalho Rafaella ◽  
Alves Rodrigues dos Santos Lima Luciana ◽  
...  
2020 ◽  
Vol 11 (2) ◽  
pp. 8608-8625

It should be remembered that bacteria continue to spread and develop new types of resistance, so further actions are needed to deal with antibiotic resistance. As a result, antibacterial drugs have become less effective, resulting in the accelerated discovery of available alternative treatments, including essential oils. The aim of this work was to intensify and promote the action of two antibiotics, kanamycin, and colistin, to fight antibiotic resistance thanks to the action of essential oil obtained from the flowers of Coridothymus capitatus grown on the Iblei mountains. To this end, a comparison of biological and chemical assays was carried out. The results showed a broad antimicrobial power of the essential oil itself and a great synergistic activity in combination with Kanamycin and Colistin against multidrug-resistant bacteria. These combinations increased the range of antibiotics, leading us to speculate that it could be incorporated into new pharmaceutical formulations for therapies of infections caused by increasingly dangerous bacteria. Antibiotic resistance represents an ever-greater danger to human health. This work re-evaluates the use of colistin and kanamycin thanks to the synergistic action found with the addition of a natural substance to pave the way for new therapeutic strategies.


2019 ◽  
Vol 64 (3) ◽  
Author(s):  
Shawn M. Zimmerman ◽  
Audrey-Ann J. Lafontaine ◽  
Carmen M. Herrera ◽  
Amanda B. Mclean ◽  
M. Stephen Trent

ABSTRACT The threat of diminished antibiotic discovery has global health care in crisis. In the United States, it is estimated each year that over 2 million bacterial infections are resistant to first-line antibiotic treatments and cost in excess of 20 billion dollars. Many of these cases result from infection with the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which are multidrug-resistant bacteria that often cause community- and hospital-acquired infections in both healthy and immunocompromised patients. Physicians have turned to last-resort antibiotics like polymyxins to tackle these pathogens, and as a consequence, polymyxin resistance has emerged and is spreading. Barring the discovery of new antibiotics, another route to successfully mitigate polymyxin resistance is to identify compounds that can complement the existing arsenal of antibiotics. We recently designed and performed a large-scale robotic screen to identify 43 bioactive compounds that act synergistically with polymyxin B to inhibit the growth of polymyxin-resistant Escherichia coli. Of these 43 compounds, 5 lead compounds were identified and characterized using various Gram-negative bacterial organisms to better assess their synergistic activity with polymyxin. Several of these compounds reduce polymyxin to an MIC of <2 μg/ml against polymyxin-resistant and polymyxin-heteroresistant Gram-negative pathogens. Likewise, four of these compounds exhibit antimicrobial activity against Gram-positive bacteria, one of which rapidly eradicated methicillin-resistant Staphylococcus aureus. We present multiple first-generation (i.e., not yet optimized) compounds that warrant further investigation and optimization, since they can act both synergistically with polymyxin and also as lone antimicrobials for combating ESKAPE pathogens.


2016 ◽  
Vol 23 (8) ◽  
pp. 738-747 ◽  
Author(s):  
Esteban N. Lorenzón ◽  
Norival A. Santos-Filho ◽  
Matheus A. S. Ramos ◽  
Tais M. Bauab ◽  
Ilana L. B. C. Camargo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document